https://medicine.ouhsc.edu/Academic-Departments Parent Page: Academic Departments id: 22555 Active Page: Facultyid:23541

Faculty

Internal Medicine

Richard F. Harty, MD

Professor of Medicine Emeritus


COMD 7400
800 Stanton L Young Blvd
Oklahoma City, OK

405-271-5428

Richard-Harty@ouhsc.edu


Dr. Harty is a board-certified gastroenterologist and professor Emeritus at the University of Oklahoma College of Medicine. He has a special interest in Irritable Bowel Disease and Crohn’s. Dr. Harty completed fellowship at University of Florida. He completed a residency at the University of Virginia Hospital and earned his medical degree from Georgetown University School of Medicine.


Academic Section(s):

Digestive Diseases and Nutrition


Education:

Georgetown University School of Medicine, Washington, D.C.
MD 1968
 


Board Certification(s):

American Board of Internal Medicine
1972

Gastroenterology
1975


Residency:

University of Virginia Hospital, Charlottesville, VA
Internal Medicine
1971


Fellowship:

Hershey Medical Center of Pennsylvania, Hershey, PA
Gastroenterology
1973

 

University of Florida, Gainesville, FL
Research GI Fellowship
1973


Clinical/Research Interests:

Irritable Bowel Disease

Crohn’s & Colitis

GI clinical trials research


Funding:

NIH & VA Research Grants, 1980-1997

Harty, R. F. (Site PI), Daniel, B. V. (Supporting Investigator), "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintaenance Therapy for Moderately to Severely Active Crohn's Disease," Sponsored by Celgene, Private Grant/Contract Number: C8329001 July 25, 2019 - March 31, 2020

Harty, R. F. (Site PI), Daniel, B. V. (Supporting Investigator), "Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease," Sponsored by Celegene, Private Grant/Contract Number: C8329101 July 25, 2019 - March 31, 2020

Harty, R. F. (Site PI), Daniel, B. V. (Supporting Investigator), "A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease (RPC01-3204)," Sponsored by Celgene Corporation, Inc, Private Grant/Contract Number: C8328901 July 16, 2019 - March 31, 2020

Harty, R. F. (Site PI), Daniel, B. V. (Supporting Investigator), "A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis," I6T-MC-AMBG, Sponsored by Eli Lilly, Private Grant/Contract Number: C8326901 May 6, 2019 - January 31, 2020

Harty, R. F. (Site PI), Daniel, B. V. (Supporting Investigator), "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis (IND# 115,243)," Sponsored by Celgene, Private Grant/Contract Number: C8319901 May 22, 2018 - January 31, 2020


Select Publications:

RNS Profile